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Research Article
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Patient awareness and approval for an opt-out
genomic biorepository
Aim: In this study, we sought to assess patient awareness and perceptions of an opt-out biorepository.
Materials & methods: We conducted exit interviews with adult patients and parents of pediatric patients
having their blood drawn as part of their clinical care at Vanderbilt University Medical Center (TN, USA).
Results: 32.9% of all patients and parents of pediatric patients report having heard of the opt-out
biorepository, while 92.4% approve of this research effort based on a brief description. Awareness that
leftover blood could be used for research increased among adult patients during the study period, from
34.3 to 50.0%. Conclusion: These findings will inform ongoing assessments of the suitability of opt-out
and opt-in methods as alternatives to written informed consent for inclusion in a biorepository.
KEYWORDS: biorepository n exit interviews n human nonsubjects biorepository
n opt‑out research n research ethics

A value core to all modern statements on the
ethics of human research is that participation
in research should be fully voluntary [1–3] . In
practice, the value of voluntariness is often associated with the assumption of risk. For example, US regulations on research with human
subjects require that participants be provided
with detailed information on relevant risks and
benefits, and signal their willingness to take on
risk by signing an informed consent document.
Researchers conducting studies involving very
limited risks (such as epidemiological research
using existing data) need not seek written
consent.
There are, however, other reasons to ensure
that participation in research is voluntary. The
principle of respect for persons, in particular,
implies that the wishes of humans contributing
samples and data should be respected even when
they are not engaging in research as human
subjects [4] . Failure to show this form of respect
threatens public support for research [5] . We have
previously coined the term ‘human nonsubjects
research’ to highlight the respect that is due to
persons who donate samples for research, even
when those persons are not engaged in research
as research subjects [6,7] .
The availability of new technologies such as
next-generation sequencing and advanced computational approaches create opportunities to
conduct research in new ways, which in turn
create the need to re-examine how voluntary
participation can be obtained within the scope of
existing research regulations and ethical values.
Recent innovations, for example, have made it

possible to generate useful health-related findings using large data sets that contain medical
record data and biosamples. These collections
may be referred to as biorepositories or biobanks. This type of research can be conducted
using only de-identified data and thus may be
considered to involve risk similar to epidemiological research. In fact, US human research
protections regulations define research on deidentified information and biosamples from
humans as exempt from the requirements of the
Common Rule, including those for informed
consent [101] . These regulations do not require
complete anonymization of information. Indeed,
it may not even be possible to obtain complete
anonymization [8,9] . Current regulations instead
provide guidance on the information that must
be removed or altered in order for data to be
considered deidentified [102] .
Given that written informed consent may not
be required by regulations, but that respect for
research participants remains important, several
institutions have begun to explore whether optin and opt-out approaches can be used effectively
to obtain permission from participants to use
their medical record information and leftover
biosamples for biorepository research [10,11] .
Opt-in and opt-out methods are designed to
minimize the burdens of eliciting voluntary participation from a large number of patients while
providing those who do not wish to contribute
the opportunity to exercise that preference. Such
opportunities for participants to have a say are
especially important in research involving nextgeneration sequencing, since some patients will
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have concerns about the private or potentially
stigmatizing information that may be revealed
through sequencing technologies.
Unlike informed consent methods, opt-in and
opt-out approaches assume that any decision not
to participate is likely to be based on a patient’s
general disposition toward the idea of research on
their biosamples and that participants can usually make this decision with a simple overview
of what is involved in the research. The primary
aim is to ensure that any decisions about participation or nonparticipation authentically reflect a
person’s preferences. Comprehensive information
about the research is not always needed to attain
that end. It has been argued that providing comprehensive information to research participants
is more relevant to the aim of protection against
liability and that providing participants with
relatively brief information about research studies may actually improve their ability to make
effective decisions [12] . In this spirit, opt-in and
opt-out documents are usually provided as short
permission forms focused on notifying patients
that samples are being collected for research and
that patients have a choice about whether their
sample will be included.
If opt-in or opt-out approaches are to be considered as suitable alternatives to obtaining written informed consent, the forms and other notification efforts they utilize must be effective with
respect to making potential participants aware
of the research and providing them with enough
information to make an effective decision. Since
the default for opt-out methods is inclusion in
research, biorepositories utilizing this approach
must additionally ensure that participants recognize that they have the opportunity to opt-out
of participation.
In this article we report the findings of an
exit interview study conducted with patients at
Vanderbilt University Medical Center (TN, USA)
on BioVU, an opt-out biorepository composed of
leftover clinical blood samples and de-identified
medical record information. At the time this study
was conducted, patients were asked to sign a twopage ‘consent for treatment’ form at the time of
their first visit to an outpatient clinic and then
once every 12 months. A description of BioVU
along with an opt-out checkbox were included
in this “consent for treatment” form just above
the signature line. Patients wishing to opt-out
of inclusion of their biosample in BioVU were
prompted to check the box indicating this preference. The language used in this form is provided
in Supplementary Figure 1A (see online www.futuremedicine.com/doi/suppl/10.2217/PME.13.34).
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Through this form, all patients receiving care at
a Vanderbilt outpatient facility were notified of
BioVU and their opportunity to opt-out. In order
to supplement this form, patients were also notified of BioVU through posters and pamphlets in
clinical areas, and advertisements in local publications. The interview study reported here was
intended to evaluate whether the procedures
adopted by BioVU were adequate in terms of
informing patients of this research and making
them aware that opportunities to opt-out are provided. We explore here the implications of these
findings for the policies that should be adopted by
individual opt-out biorepositories, as well as their
implications for the larger debate on alternative
methods for ensuring voluntary participation in
research.

Materials & methods

Survey overview
From 2009 to 2012, we conducted exit interviews with adult patients and parents of pediatric
patients who were having their blood drawn at
outpatient phlebotomy areas. This study involved
three distinct cohorts. First, we conducted interviews in 2009 with adult patients having blood
drawn at the two busiest adult outpatient phlebotomy areas in Vanderbilt University Medical
Center (Adult time point 1 or Adult 1 cohort).
During this period, the biorepository was relatively new and collected samples from adult
patients only. In 2010, immediately following
expansion of the biorepository to include pediatric patients, we began interviewing the parents
of pediatric patients who were having their blood
drawn at the two busiest outpatient phlebotomy
areas in the Monroe Carell Jr. Children’s Hospital at Vanderbilt (Nashville, TN, USA; Pediatric cohort [Peds cohort]). Finally, in 2011, we
began a second round of exit interviews at the
same adult phlebotomy areas where the Adult 1
cohort sample was collected. This second sample
was obtained to determine whether awareness
and approval for the opt-out biorepository had
changed as the biorepository became better established and public notification efforts continued
(Adult time point 2 or Adult 2 cohort).
No identifiable information about respondents was viewed or recorded at any time. The
Vanderbilt Institutional Review Board reviewed
this study and approved its classification as an
exempt study.

Survey design
The survey instruments used for each of the
three cohorts were similar. The instrument
future science group
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used for the Adult 1 cohort was designed collaboratively by two pediatricians with expertise
in research ethics issues (KB Brothers and EW
Clayton) and a sociologist with experience in
survey design (DR Morrison). The instrument
used for the Peds cohort was designed by the
same team. It was modified from the Adult 1
cohort instrument to account for pediatricspecific issues (i.e., the possibility that respondents might view the collection of their child’s
sample differently from the collection of their
own sample) and based on feedback from the
study personnel who fielded the Adult 1 cohort
survey. Revisions incorporated into the design of
the Adult 2 cohort instrument were intentionally minimized in order to facilitate comparisons
with the earlier adult cohort. The Adult 2 cohort
instrument was identical to the Adult 1 cohort
with the exception of one additional question. As
shown in Supplementary Figures 2–4, all three instruments were designed with branching logic; the
questions asked of each participant were determined by his or her earlier responses. For this
reason, several questions were posed to only a
subset of respondents.

Survey administration
All three cohorts were collected in clinical practice settings where information about the optout biorepository was communicated through
posters, pamphlets and consent-for-treatment
forms. In order to increase the number of exit
interviews conducted, interviewers coordinated
with staff at each phlebotomy area to identify
the periods each week when the most clinical
blood samples were typically drawn. During
these times, an interviewer was stationed outside
the phlebotomy area and attempted to approach
every patient (or pediatric patient’s parent) as
they entered or exited the phlebotomy area. The
interviewer identified qualified participants by
asking “[Did you/will you] have your blood
drawn today?” Only potential participants who
answered affirmatively were invited to complete
the survey. The interviewer explained that the
survey would take about two minutes and would
be completed anonymously. Interviewers also
explained that respondents could choose to end
the survey at any time.
Otherwise qualified patients were excluded
from our study if they declined participation or
were unable to complete the survey in English.
In addition, when more than one patient entered
or exited the phlebotomy area at the same time,
the single interviewer was only able to approach
one. Interviewers tallied the number of potential
future science group
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respondents who were not included in our study
for each of these reasons. Potential respondents
who exited the phlebotomy area at a time when
the interviewer was busy were counted based on
the observations of the interviewer; it is possible
that some patients exited the phlebotomy area
but were not noticed by the interviewer.
After obtaining agreement to participate,
interviewers verbally administered the survey
and recorded participant responses. As demonstrated on the provided interview guides
(Supplementary Figures 2–4) , some questions required
interviewers to code open-ended participant
responses. Interviews with adult patients
included the collection of participant demographics, including age, gender and self-identified ethnicity. Interviews with the parents of
pediatric patients involved collection of demographics for both the adult participant and the
child having his or her blood drawn.

Statistical analysis
The primary outcomes for this study were:

Awareness of the Vanderbilt DNA databank;

Awareness that leftover blood could be used
for research;

Support for the biorepository.
An analysis of the two adult groups (Adult 1
cohort vs Adult 2 cohort) allowed us to investigate changes over time. Inclusion of the Peds
cohort allowed us to explore whether differences
existed between adult patients and parents of
pediatric patients. Initially, chi-squared techniques were used to test for differences in gender
and ethnicity between the two adult groups in
order to reveal potential confounders for changes
over time; an independent samples t-test was performed to test for differences in age. Similarly,
c2 and analysis of variance techniques were used
to test whether parents of pediatric patients differed from the two adult groups. c2 techniques
were used to test whether surveyed participants
differed significantly in age, gender or ethnicity
from the total patient population being seen in
the medical center during that time period.
c2 techniques were used to test (unadjusted)
for differences in the proportions of individuals
in each group who:

Had heard of the Vanderbilt DNA databank;

Understood that leftover blood could be used
for research;

Supported the DNA databank.
www.futuremedicine.com
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Similarly, c2 techniques were used to test
for differences in the proportion of adults who
recalled or preferred to opt-out of the DNA databank between the two time points. Multivariable
logistic regression techniques were used to test
(adjusted for age, ethnicity and gender) whether
inclusion in the Adult 1, Adult 2 and Peds
cohorts predicted responses to questions related
to the four primary outcomes. We performed a
descriptive analysis of the reasons patients and
parents of pediatric patients gave for supporting
or opposing the DNA databank.

Results

Demographics & participation rates
Our adult participants at Adult time point 1
were significantly more likely to be black compared with the total population of adult out
patients seen in 2009 (19.5 vs 7.3%; p < 0.001).
The adult cohort interviewed at Adult time point
2 was significantly more likely to be white (87.5
vs 61.9%; p < 0.001) when compared with the
total population of adult patients seen in 2011
and 2012 (Table 1) . Mean age differed significantly between the two adult cohorts (57.8 vs
52.1 years; p = 0.038). Respondents in adult 2
cohort were significantly less likely to be black
(19.5 vs 6.3%; p = 0.010) and significantly less
likely to be other (2.6 vs 6.3%; p < 0.001) when
compared with adult 1 cohort (Table 1) .
As expected, parents of pediatric patients
who we interviewed were significantly different
from adult patient participants. Parents were
significantly more likely to be female (83.8 vs
58.4% and 55.0%; p < 0.001), younger (29.3 vs
57.8 years and 52.1 years; p < 0.001) and more
likely to be a member of a minority racial/ethnic
group (41.2 vs 22.1% and 12.5%; p < 0.001).
The children whose parents were interviewed
for our study were fairly representative of all
pediatric patients seen in outpatient areas of the

children’s hospital, with the exception of age; the
children of respondents were younger compared
with the general pediatric patient population
(p < 0.001) (Table 2) .
As a result of differences in patient populations, parents of pediatric patients were more
likely to be unable to participate because they
were non-English speaking compared with adult
patients (Tables 3 & 4) . In addition, more potential
participants refused participation in the Adult
2 cohort as compared with the other cohorts.
Overall response rates were robust across all
three cohorts (>60%).

Primary outcomes
Unadjusted, as seen in Table 5, respondents in
the Peds (18.8 vs 48.1% and 32.5%; p < 0.001)
and Adult 2 cohorts (32.5 vs 48.1%; p = 0.047)
were significantly less likely to have heard of the
DNA databank. On the other hand, respondents
in the Adult 1 cohort were significantly less likely
to understand that leftover biospecimens could
be used for research (34.3 vs 50.0% and 46.3%;
p = 0.040).
Despite relatively low awareness, a large majority of all three cohorts supported the DNA databank after a brief explanation (n = 219, 92.5%),
and parents of pediatric patients supported a
DNA databank for children (n = 71, 88.8%).
As seen in Ta bl e 6 , the logistic regression models fit the data well, as indicated by
Hosmer–Lemeshow p-values greater than 0.05.
Following adjustment, adult patients at Adult
time point 2 remained significantly more likely
to recall signing a consent for treatment form
(overall response [OR]: 2.10; 95% CI: 1.02–
4.32; p = 0.042) and to understand that their
leftover specimens could be used for research
(OR: 1.91; 95% CI: 1.07–3.73; p = 0.041) when
compared with adult patients at Adult time point
1. The decrease from Adult time point 1 to Adult

Table 1. Adult demographics stratified by time point.
Demographic

Adult 1
All adult
p-value
Adult 2
cohort
outpatients in
cohort
cohort
(n = 77) (%) 2009
versus all (n = 80) (%)
(n = 222,304) (%)

All adult
p-value
p-value
outpatients
cohort
Adult 1 versus
2011–2012
versus all 2 cohort
(n = 207,646) (%)

Female
Ethnicity

45 (58.4)

128,085 (57.6)

0.884

44 (55)

119,356 (57.5)

0.654

0.664

White 60 (77.9)

155,339 (69.9)

0.124

70 (87.5)

128,442 (61.9)

<0.001*

0.112

Black

16,291 (7.3)

<0.001*

5 (6.3)

15,274 (7.4)

0.705

0.010*

50,674 (22.8)

<0.001*

5 (6.3)

63,930 (30.7)

<0.001*

<0.001*

65.0 (0.91)

0.095

52.1 (1.64)

52.1 (0.88)

0.914

0.038*

15 (19.5)

Other 2 (2.6)
Age (SD)

57.8 (1.74)

*Significant at the 0.05 level.
SD: Standard deviation.
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Table 2. Demographic variables of pediatric patients whose parents participated in our study in comparison
with all pediatric patients with outpatient visits during the study period.
Demographic

Peds cohort (n = 80) (%)

All pediatric outpatients
(n = 63,199) (%)

p-value

Age of child (SD)

4.4 (0.53)

8.04 (5.31)

<0.001*

Female (child)
Child ethnicity

Location

36 (45.0)

29,782 (47.1)

0.704

White

45 (56.3)

30,806 (48.7)

0.180

Black

19 (23.8)

8309 (13.1)

0.005*

Other

16 (20.0)

24,084 (38.2)

0.001*

Multispecialty clinic

32 (40.0)

–

–

Primary care clinic

48 (60.0)

–

–

*Significant at the 0.05 level.
Peds cohort: Pediatric cohort; SD: Standard deviation.

time point 2 in the proportion of respondents
who reported having heard of the DNA databank remained following adjustment (OR: 0.51;
95% CI: 0.26–1.01; p = 0.054), although this
change became nonsignificant. Females were
more likely to have heard of the DNA databank
(OR = 2.34; 95% CI: 1.23–4.44; p = 0.009) and
older individuals were more likely to support the
DNA databank (OR: 1.10; 95% CI: 1.02–1.18;
p = 0.016).
As seen in Table 7, the most common reason
provided by adult patients for supporting the
biorepository was the potential for it to support
research that improves understanding of diseases
(coded by interviewers as “doctors will study diseases”). As seen in Table 8 , parents of pediatric
patients most often reported the potential for the
biorepository to benefit others as a reason that
they support the biorepository. Among those
respondents who reported that they oppose the
biorepository, two out of seven adult patients and
two out of four parents of pediatric patients cited
privacy concerns.

Discussion

Awareness of the DNA databank
& use of leftover blood for research
We found that adult patients surveyed in 2009
were more likely to report having heard of the

DNA databank in comparison to adult patients
surveyed from 2011 to 2012 (48.1 and 32.5%,
respectively), even though awareness that leftover blood could be used for research increased
during this period, from 34.3 to 50.0%. We
theorize that even though patients were increasingly aware that leftover blood could be used for
research, they became less likely to recognize the
name ‘DNA databank’, in part because program
literature increasingly used the name ‘BioVU’ to
describe this resource. However, conveniencebased samples in pragmatic settings are sensitive
to a range of procedures throughout a program.
Thus, our data are best suited to provide both
a benchmark and tracking for key measures,
such as awareness and perceptions of the biorepository. This methodology does not facilitate
attribution of trends to specific causes.
Although patients may not have been able to
recognize that ‘DNA databank’ and ‘BioVU’
refer to the same research resource, the concept
that leftover blood could be used for research is
a consistent concept across all patient notification efforts. For this reason, we believe it is the
more accurate surrogate for awareness of this
program. In an earlier study, we demonstrated
that only 32% of patients recalled seeing posters intended to notify them about BioVU [13] .
Based on these data, notification efforts were

Table 3. Reasons for noninclusion.
Cohort

Reason for noninclusion
Patient/parent
refused, n (%)

Staff busy, n (%)

Non-English
speaking, n (%)

Adult 1 (n = 35)

17 (48.6)

17 (48.6)

1 (3.8)

Adult 2 (n = 48)

34 (70.8)

14 (29.2)

0 (0.0)

Peds (n = 35)

8 (22.9)

4 (11.5)

23 (65.6)

Peds: Pediatric.

future science group

www.futuremedicine.com

353

Research Article

Brothers, Westbrook, Wright et al.

Table 4. Response rates.
Cohort

Total potential respondents (included and not included)
Response rate† (%)

Refusal rate† (%)

Adult 1 (n = 112)

68.8

15.2

Adult 2 (n = 128)

62.5

26.6

Peds (n = 115)

69.6

7.0

Rates are calculated according to the American Association for Public Opinion Research guidelines and assume that all
nonparticipants would have been eligible [23].
Peds: Pediatric.
†

markedly expanded, including handing pamphlets to all new patients, expanding posters to
both phlebotomy and clinic areas and placing
advertisements in local publications. Based on
the findings of this study, these efforts seem to
have been somewhat successful.
Although this increase in awareness is heartening, it is not clear what an appropriate goal
should be for this value. Even research participants who complete an informed consent process
are not always aware that they are engaged in
research. The percentage of participants in prior
studies who are able to correctly identify that
they are participating in research ranges from
56.4 to 92.2% [14–18] . Even those who recognize that they consented to research often do
not recall the aims of that research; the proportion who do ranges from 33.3 to 55.2% [14,19] .
Despite these findings, at least one study has
indicated that as much as 100% of biorepository participants are able to identify this activity
as research [20] .
By comparing these previous findings with the
results reported here, we believe that the opt-out
procedures utilized by BioVU are not yet optimal. Informed by these data and due to unrelated
institutional interest in improving the quality of
the outpatient consent to receive treatment process, the entire medical center is currently transitioning from the paper-based process described

above to a kiosk-based consent process. Instead
of signing a two-page paper form every twelve
months, patients will now be asked to acknowledge each screen of information one-at-a-time.
This includes a dedicated screen that includes
a description of BioVU using language that has
been rewritten for clarity and simplicity. The
new language used in the kiosk-based consent is
provided in Supplementary Figure 1B. We hypothesize
that, since this new process requires an explicit
acknowledgement from patients that they have
read the presented information, patient awareness of BioVU will improve.
We have also implemented ongoing exit
interviews with patients based on the methods
described in this report. These interviews will
provide critical information in ongoing quality
assurance efforts and will allow evaluation of
whether the expanded notification methods will
result in a higher level of awareness among our
patient population.

Approval of the opt-out approach to
biobanking
Following a description of the biorepository, the
vast majority of respondents report approval for
this approach to sample collection for research
on human health. This finding has been remarkably consistent across a range of populations and
survey approaches. We recently reported on

Table 5. Outcomes studied stratified by cohort.
Variable

Adult 1
Adult 2
p-value Adult 2 Peds cohort p-value
cohort
cohort
vs Adult 1
(n = 80) (%) Peds vs Adult 1
(n = 77) (%) (n = 80) (%) cohort
& 2 cohorts

Previously heard of DNA databank

37 (48.1)

26 (32.5)

0.047*

15 (18.8)

<0.001*

Understood leftover specimens could be used
for research

25 (34.3)

40 (50.0)

0.026*

37 (46.3)

0.475

Recall previously choosing to opt-out of the
DNA databank

2 (2.6)

2 (2.5)

0.969

–

–

Support DNA databank

68 (88.3)

76 (95.0)

0.129

75 (93.8)

0.245

Support DNA databank for children

–

–

–

71 (88.8)

–

*Significant at the 0.05 level.
Peds cohort: Pediatric cohort.
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Table 6. The multivariable logistic regression models predicting primary outcomes.
Outcome
(Hosmer–Lemeshow
p-value)

Predictor

OR

95% CI of OR

p-value

Ref.

–

–

2.10

1.02–4.32

0.042*

Peds cohort

1.68

0.69–4.10

0.178

White

0.67

0.35–1.31

0.676

Female

1.03

0.55–1.91

0.931

Age

1.00

0.98–1.02

0.963

Adult 1 cohort

Ref.

–

–

Adult 2 cohort

0.51

0.26–1.01

0.054

Peds cohort

0.21

0.08–0.51

0.001*

White

1.15

0.57–2.35

0.692

Female

2.34

1.23–4.44

0.009*

Age

1.00

0.98–1.02

0.953

Adult 1 cohort

Ref.

–

–

Adult 2 cohort

1.91

1.07–3.73

0.041*

Peds cohort

1.10

0.48–2.50

0.821

White

1.08

0.57–2.04

0.822

Female

1.76

0.97–3.18

0.061

Age

0.99

0.97–1.01

0.248

Adult 1 cohort

Ref.

–

–

Adult 2 cohort

2.44

0.74–8.53

0.147

Peds cohort

2.25

0.72–7.32

0.204

White

2.08

0.58–3.62

0.182

Female

1.60

0.48–2.57

0.697

Age

1.10

1.02–1.18

0.016*

Recognize consent for
Adult 1 cohort
treatment form (p = 0.575)
Adult 2 cohort

Have heard of DNA
databank (p = 0.635)

Understand leftover blood
could be used for research
(p = 0.125)

Support DNA databank
(p = 0.875)

A Hosmer–Lemeshow p-value greater than 0.05 suggests the model fits the data well.
*Significant at the 0.05 level.
OR: Overall response; Peds cohort: Pediatric cohort; Ref.: Reference.

large-scale surveys with members of the Nashville community and employees of Vanderbilt
University (TN, USA) demonstrating rates of
approval (93.9 and 94.6%, respectively) nearly
identical to those identified in this study [21] .
Although we did interview a small number of
adult patients who reported previously opting
out of BioVU (2.5%) and a small number who
opposed the biobank (7.6%), this sample was
inadequate to conclusively identify the reasons
that usually motivate this decision.

Voluntariness of participation
We believe there are at least three empirical
questions relevant to assessing whether the optout approach to building biorepositories can
effectively ensure that inclusion of biosamples
is voluntary:
future science group


Are patients made aware of the research
through notification efforts and the opt-out
form?

Are patients provided with enough information
to make an effective decision?

Are patients aware of not only the research,
but also of their opportunity to opt-out?
The present study addresses only the first
empirical question, although our answer is an
incomplete one. Even though we were able to
determine that roughly half of patients report
that they are not aware that their leftover blood
could be used for research, we are not able to
discriminate among the possible explanations for
this finding. It is likely that some patients have
simply never noticed the posters in clinic areas,
www.futuremedicine.com
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Table 7. Reasons given by adult patients for supporting or opposing the DNA
databank.
Response

Number of respondents (%)
Adult 1 cohort

Adult 2 cohort

Reasons for supporting :
Research might benefit me or my family
Research is being done at Vanderbilt
Collection of samples is helpful to scientists
Doctors will study diseases
Other

n = 68
11 (16.2)
4 (5.9)
21 (30.9)
31 (45.6)
4 (5.9)

n = 77
17 (22.4)
3 (3.9)
5 (6.6)
36 (47.4)
47 (61.8)

Reasons for opposing† :
I do not know how my DNA will be used
I do not believe my information is safe
Other

n=6
2 (33.3)
1 (16.7)
3 (3)

n=1
0 (0)
1 (100)
1 (100)

†

Respondents were permitted to provide multiple reasons.

†

pamphlets handed out in clinics and opt-out
language included on the consent for treatment
form. Other patients may have seen one or more
of these notifications, but did not understand its
content. These are the causes that we are most
interested in eliminating, since they are particularly relevant to the question of voluntariness of
inclusion in BioVU. However, there are certainly
other possible reasons that patients report not
being aware of the DNA databank. For example,
previous research on participant recall in the
setting of informed consent to research participation, as described above, indicates that even
individuals who undergo a detailed informed
consent process do not recall the key elements
of that information.
Indeed, our results indicate that even though
we can assume that every patient has signed a
consent for treatment form in the past and therefore has had an opportunity to read information
pertaining to BioVU (since medical center policies require that a signed copy of the consent for
treatment form must be in the electronic medical record in order for an outpatient to receive
treatment), 23.8% of parents either report that
they have never seen the form or that they are

not sure whether they have seen the form. Since
we do not have access to respondents’ administrative records, we are unable to infer what has
caused this lack of recall (i.e., parents who signed
these forms recently yet report they have never
seen them may not have been attentive to what
they were signing; parents who signed the forms
months ago may have just forgotten about them).
However, it does appear that recognition of the
form is a relatively strong predictor of awareness
that leftover blood could be used for research;
those patients who report signing the consent for
treatment form on the day they responded to the
survey are significantly more likely to be aware
that leftover blood could be used for research
compared with those who do not recall signing
the form (61 vs 37%; p = 0.0007).

Limitations
This study has a number of limitations, several of
which have been mentioned above. Perhaps the
most significant limitation of this study is that
all variables are based on patient recall. We did
not seek permission from respondents to access
their administrative records, so we do not know
which of them had opted out of the biorepository

Table 8. Reasons given by parents of pediatric patients for supporting or opposing
including children in the DNA databank.
Response

Number of respondents (%)

Reasons for supporting :
Benefit other people
Benefit me or my family
Benefit people with same disease
I don’t see a reason not to support it

n = 71
60 (89.6)
6 (9.0)
4 (6.0)
11 (16.4)

Reasons for opposing† :
Concerned about privacy of DNA information
Concerned about privacy of health information
Other

n=4
1 (25.0)
1 (25.0)
2 (50.0)

†

Respondents were permitted to provide multiple reasons.

†
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in the past or when each last viewed and signed
the ‘consent for treatment’ form. We also do
not know who is actually included in the biorepository, since all data in the biorepository is
de-identified.
An additional limitation is that all three
cohorts were collected as convenience samples.
In order to maximize the number of patients
who could be surveyed, interviewers focused on
the busiest phlebotomy areas on their busiest
days of the week. However, all four of the phlebotomy areas where patients were interviewed
(two adult, two pediatric) serve multiple clinics. One of the pediatric locations and one of
the adult locations serve primarily subspecialty
clinics, while the remaining two locations serve
primarily primary care patients. Interviewers
were intentional in balancing interviews conducted at each location. We have assessed selection bias in two ways: by tallying the patients
who were not included in our study (Tables 3 & 4)
and by comparing our sample with the total
outpatient population (Tables 1 & 2) . The former
method indicates a strong response rate for this
survey and the latter method demonstrates that
our sample is reasonably representative of the
patient population of interest.
The absence of comparison groups also significantly limits our ability to interpret the findings
of this study. We have identified only one previous
study evaluating awareness of an ongoing research
project involving an opt-out dimension, although
the research involved – a study of resuscitation
algorithms in a pediatric intensive care unit – is
significantly different from that performed using
a genomic biorepository [22] . As other institutions develop biorepositories based on opt-in and
opt-out models, patient awareness and approval
should be evaluated. This experience across settings will help establish best practices for patient
notification and meaningful benchmarks for
awareness of opt-in and opt-out approaches to
biorepository research.

Conclusion
We found that many patients and parents of pediatric patients having blood drawn as a part of their
medical care were not aware of our opt-out biorepository that collects leftover clinical samples to
be used for research on health, although the vast
majority approved of this research effort. While
recognition of the ‘DNA databank’ decreased over
time among adult patients, awareness that leftover
blood could be used for research increased. We
attribute this increase to ongoing patient notification efforts, although the relatively low level
future science group
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of awareness in our sample indicates that additional improvements in these efforts are needed.
Additional empirical research will be needed to
inform a thorough analysis of the suitability of
opt-out methods to ensure voluntary participation
in research.

Future perspective
In future work we hope to conduct interviews with
patients who have given us consent to access their
electronic administrative record. This approach
will not only allow us to assess whether patients
who recently signed consent for treatment forms
are more likely to be aware of BioVU, but also
to assess whether patients who report a desire to
opt-out of inclusion have successfully opted out
in the past. These additional data will help us
address our overarching aim of examining the
effectiveness of opt-out procedures for ensuring
voluntary participation in research.
We hope other biorepositories utilizing optout and opt-in methods will conduct similar
empirical research in their own research settings.
These new empirical findings will help inform
the follow-on ethical and policy analysis that
will be needed to determine the appropriateness
of opt-in and opt-out methods, since, in certain
circumstances, traditional informed consent can
be impractical or can pose a significant barrier to
answering important research questions.
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Executive summary
Background
 ‘Human nonsubjects’ approaches to research, including opt-in and opt-out methods, represent attempts to respect the preferences of
individuals on the research uses of their biosamples and/or medical information, even though they are not engaging in research as
subjects.
 Empirical data is needed in order to assess whether the opt-out approach to building a biorepositories can effectively ensure that
inclusion of biosamples is voluntary.
Materials & methods
 In this manuscript, we report on exit interviews we conducted to assess patient awareness of one particular opt-out biorepository.
 The primary outcomes for this study were:
– Patient awareness of the Vanderbilt DNA databank;
– Patient awareness that leftover blood could be used for research;
– Patient support for the biorepository.
Results
 Adult patients surveyed in 2009, less than 2 years after the biorepository started, were more likely to report having heard of the DNA
databank in comparison with adult patients surveyed from 2011 to 2012. At the same time, awareness that leftover blood could be
used for research increased during this period.
 Parents of pediatric patients were less likely than adult patients to have heard of the DNA databank. However, a comparatively large
number of them were aware that leftover blood could be used for research.
 Despite relatively low awareness, a large majority of patients and parents of pediatric patients supported the DNA databank after a
brief explanation and a comparable majority of parents supported a DNA databank for children.
Discussion
 Additional research is needed to determine whether high levels of awareness can be obtained through patient notification efforts,
including opt-out forms, posters and brochures.
 Additional research is also needed to assess whether opt-out approaches can be effective at making patients aware of the opportunity
to opt out and providing them with enough information to make an effective choice.
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